Zealand Pharma (ZEAL.CO)

Executive Summary

Zealand Pharma is a Danish biotechnology company focused on peptide-based therapies for metabolic and gastrointestinal diseases, with a strong emphasis on obesity, type 2 diabetes, and rare conditions. Its lead asset, glepaglutide, is in Phase 3 for Short Bowel Syndrome (SBS), a rare disease with high unmet need. Top-line data from two pivotal trials (NCT03905707, NCT04881825) are expected in mid-2026, which could support a New Drug Application submission. The company also has a portfolio of earlier-stage candidates, including dasiglucagon for congenital hyperinsulinism and novel obesity therapies leveraging its peptide engineering platform. With a market cap of ~$21B and two approved products, Zealand is positioned for significant value inflection pending glepaglutide's success. Given the imminent Phase 3 readout and the potential to address a critical gap in SBS treatment, Zealand represents a high-conviction opportunity. The company's proprietary technology and strategic partnerships (e.g., with Novo Nordisk and other pharma) further underpin its growth trajectory. However, risk remains around clinical trial outcomes and competitive dynamics in the obesity space. Overall, Zealand's near-term catalysts and established pipeline merit a strong conviction score.

Upcoming Catalysts (preview)

• Q3 2026Glepaglutide Phase 3 top-line data in Short Bowel Syndrome70% success
• H1 2027Potential regulatory submission for glepaglutide in SBS60% success
• H2 2026Initiation of Phase 2 obesity study for dual agonist ZP983050% success